Close Menu

NEW YORK – Dante Labs announced Tuesday its Immensa software received CE-IVD marking for the interpretation of whole-genome sequencing data in a clinical setting at scale.

The software generates personalized reports for pharmacogenomics, rare diseases, predisposition to common diseases, and nutrigenomics, and integrates guidelines from the American College of Medical Genetics, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.